SCHEMBL5406076

SCHEMBL5406076

CC(C)CC=C(Cn1nc2c(c1-c1nn(C)cc1Cl)c(=O)n(C)c(=O)n2CC(C)C)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 5/20 0.41
PDE1B Q01064 5/20 0.41
PDE1C Q14123 5/20 0.41
PDE2A O00408 3/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.32
PDE5A O76074 4/20 0.32
CYP3A4 P08684 1/20 0.32
CFTR P13569 1/20 0.32
TSHR P16473 1/20 0.32
PDE4A P27815 1/20 0.32
MAPK1 P28482 1/20 0.32
ADORA1 P30542 1/20 0.32
SCN1A P35498 1/20 0.32
PDE6C P51160 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406067 1.00 PDE1A (0.41) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5407580 0.93 PDE1A (0.41) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5407590 0.93 PDE1A (0.41) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5411144 0.84 PDE1A (0.41) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5411138 0.84 PDE1A (0.41) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5393652 0.84 PDE1A (0.40) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5393643 0.84 PDE1A (0.40) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5411154 0.82 PDE1A (0.40) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5411162 0.82 PDE1A (0.40) PDE1APDE1BPDE1CPDE2ACYP1A2
SCHEMBL5410785 0.81 PDE1A (0.39) PDE1APDE1BPDE1CPDE2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC PDE1A 4056/4885PDE1B 4206/4885PDE1C 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.